SCHEMBL6915977

SCHEMBL6915977

COCCOC(=O)c1ncccc1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.57
▸ KDM4E B2RXH2 6/20 0.56
▸ ALDH1A1 P00352 6/20 0.56
▸ ALOX15 P16050 2/20 0.56
▸ NPSR1 Q6W5P4 2/20 0.56
▸ CYP3A4 P08684 1/20 0.56
▸ MAPT P10636 1/20 0.56
▸ BLM P54132 1/20 0.56
▸ AGER Q15109 1/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.56
▸ PTPN1 P18031 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.45
▸ MAPK1 P28482 1/20 0.43
▸ MYC P01106 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ ATM Q13315 1/20 0.43
▸ NAPRT Q6XQN6 2/20 0.42
▸ LMNA P02545 1/20 0.42
▸ BRD4 O60885 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16790442 0.87 ALDH1A1 (0.57) TSHRKDM4EALDH1A1ALOX15NPSR1
SCHEMBL31037820 0.83 KDM4E (0.61) TSHRKDM4EALDH1A1ALOX15NPSR1
SCHEMBL4914014 0.83 KDM4E (0.61) TSHRKDM4EALDH1A1ALOX15NPSR1
SCHEMBL1104042 0.81 KDM4E (0.48) TSHRKDM4EALDH1A1ALOX15NPSR1
SCHEMBL29559479 0.81 KDM4E (0.67) TSHRKDM4EALDH1A1ALOX15NPSR1
SCHEMBL519094 0.81 KDM4E (0.67) TSHRKDM4EALDH1A1ALOX15NPSR1
SCHEMBL1505205 0.78 KDM4E (0.50) TSHRKDM4EALDH1A1ALOX15NPSR1
SCHEMBL2749775 0.78 KDM4E (0.50) TSHRKDM4EALDH1A1ALOX15NPSR1
SCHEMBL186286 0.78 TSHR (0.86) TSHRKDM4EALDH1A1ALOX15CYP3A4
SCHEMBL311087 0.77 KDM4E (0.71) TSHRKDM4EALDH1A1ALOX15NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004075893-A1 METHOD OF TREATMENT OF CARDIAC AND/OR RENAL FAILURE USING A CALCIUM CHANNEL BLOCKER AND AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR OR AN ANGIOTENSIN II RECEPTOR BLOCKER DIAKRON PHARMACEUTICALS, INC. (US) 2004-09-10 — — WO claimed
Send feedback